C4 Therapeutics Unveils Promising Data on CFT1946 at ESMO 2024
C4 Therapeutics Shares Insights on CFT1946 at ESMO 2024
Today's Abstract Highlights Positive Safety Profile and Early Evidence of Monotherapy Anti-Tumor Activity
Investor Webcast Set for September 13, 2024
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company specializing in targeted protein degradation, has announced significant updates regarding their Phase 1 clinical trial of CFT1946. This innovative BiDAC™ degrader specifically targets solid tumors with the mutant BRAF V600. In conjunction with the European Society for Medical Oncology (ESMO) Congress 2024, crucial clinical data indicating a favorable safety profile and anti-tumor activity has been released.
The abstract, which includes data collected up to April 12, 2024, shows encouraging results. An oral presentation is scheduled for September 13, 2024, where information will be shared from 36 patients, detailing their demographics, safety assessments, pharmacokinetics, pharmacodynamics, and anti-tumor activities evaluated using RECIST 1.1 criteria.
Details of the ESMO 2024 Presentation
Title: Preliminary Results from a Phase 1 Study of CFT1946, a Novel BiDAC™ Degrader in Mutant BRAF V600 Solid Tumors
Presentation Date and Time: September 13, 2024, at 4:10 pm CEST (10:10 am ET)
Final Publication Number: 612O
Session Category: Proffered paper session 1
Session Title: Developmental therapeutics
Location: Santander Auditorium – Hall 5
Presenter: Maria Vieito, M.D., MSc (Barcelona, Spain)
Webcast for Analysts and Investors
C4T will host a webcast on September 13, 2024, at 12:00 pm ET to discuss the findings in detail. You can access the webcast through the company’s 'Events & Presentations' page on their official website. A recorded version will be available for those who cannot attend live.
About C4 Therapeutics
C4 Therapeutics (C4T), listed on Nasdaq (CCCC), is a leader in bioscience, committed to developing innovative, targeted therapies. They leverage their TORPEDO® platform to effectively design and enhance small-molecule drugs for challenging conditions. Their proprietary approach aims to utilize the body’s natural protein recycling mechanisms to degrade harmful proteins, providing hope for difficult health challenges such as drug resistance.
Understanding CFT1946
CFT1946 is an advanced orally bioavailable BiDAC™ degrader that demonstrates strong selectivity for BRAF V600X mutations. Initial preclinical results indicate its effectiveness both in vivo and in vitro across various settings, particularly in conditions driven by BRAF V600E mutations that are resistant to standard BRAF inhibitors. This Phase 1 dose escalation study encompasses multiple solid tumor types, including colorectal cancer, melanoma, and non-small cell lung cancer. Additional trial details can be found in the clinical trial registry.
Frequently Asked Questions
What is C4 Therapeutics known for?
C4 Therapeutics is recognized for its advancements in targeted protein degradation science, focusing on creating therapies for challenging diseases.
What is CFT1946?
CFT1946 is an investigational drug targeting BRAF V600X mutations using BiDAC™ technology, showing potential in treating various solid tumors.
When will the ESMO Congress 2024 take place?
The ESMO Congress 2024 is set to occur from September 13 to 17, 2024.
How can I view the presentation from C4T?
You can watch the oral presentation during the ESMO Congress through their official event channels or the C4T website.
Where can I find more information about the trials?
For detailed information regarding clinical trials, including CFT1946, visit www.clinicaltrials.gov.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.